Use of a Conformational Switching Aptamer for Rapid and Specific Ex Vivo Identification of Central Nervous System Lymphoma in a Xenograft Model by Georges, Joseph F. (Author) et al.
RESEARCH ARTICLE
Use of a Conformational Switching Aptamer
for Rapid and Specific Ex Vivo Identification
of Central Nervous System Lymphoma in a
Xenograft Model
Joseph F. Georges1,2☯¤, Xiaowei Liu4☯, Jennifer Eschbacher3, Joshua Nichols5, Michael
A. Mooney2, Anna Joy1, Robert F. Spetzler2, Burt G. Feuerstein5, Mark C. Preul2,
Trent Anderson5, Hao Yan4, Peter Nakaji2*
1 Division of Neuroscience, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center,
Phoenix, Arizona, 2 Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph’s Hospital
and Medical Center, Phoenix, Arizona, 3 Division of Neuropathology, Barrow Neurological Institute,
St. Joseph’s Hospital and Medical Center, Phoenix, Arizona, 4 The Biodesign Institute, Arizona State
University, Tempe, Arizona, 5 College of Medicine, University of Arizona, Phoenix, Arizona
☯ These authors contributed equally to this work.
¤ Current Address: Division of Neurosurgery, Ohio University and Grant Medical Center, Columbus, Ohio
* Neuropub@dignityhealth.org
Abstract
Improved tools for providing specific intraoperative diagnoses could improve patient care.
In neurosurgery, intraoperatively differentiating non-operative lesions such as CNS B-cell
lymphoma from operative lesions can be challenging, often necessitating immunohisto-
chemical (IHC) procedures which require up to 24-48 hours. Here, we evaluate the feasibili-
ty of generating rapid ex vivo specific labeling using a novel lymphoma-specific fluorescent
switchable aptamer. Our B-cell lymphoma-specific switchable aptamer produced only low-
level fluorescence in its unbound conformation and generated an 8-fold increase in fluores-
cence once bound to its target on CD20-positive lymphoma cells. The aptamer demonstrat-
ed strong binding to B-cell lymphoma cells within 15 minutes of incubation as observed by
flow cytometry. We applied the switchable aptamer to ex vivo xenograft tissue harboring B-
cell lymphoma and astrocytoma, and within one hour specific visual identification of lympho-
ma was routinely possible. In this proof-of-concept study in human cell culture and orthoto-
pic xenografts, we conclude that a fluorescent switchable aptamer can provide rapid and
specific labeling of B-cell lymphoma, and that developing aptamer-based labeling ap-
proaches could simplify tissue staining and drastically reduce time to histopathological diag-
noses compared with IHC-based methods. We propose that switchable aptamers could
enhance expeditious, accurate intraoperative decision-making.
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Introduction
Surgical resection of brain tumors is guided by intraoperative frozen section analyses. This
technique is useful for diagnosing neoplastic tissue and identifying tumor margins [1]; howev-
er, some pathologies that require opposing treatment strategies can be a challenge to diagnose
by frozen section alone, and instead require more specific staining. For example, differentiating
some gliomas, such as oligodendroglioma or subtypes of high-grade astrocytoma from lym-
phoma can be challenging with frozen section analysis [2]. Specific diagnostic staining is typi-
cally achieved with immunohistochemistry (IHC), a staining process which is too slow to be
used intraoperatively [3]. When a diagnosis requires IHC, a biopsy will typically be performed,
and definitive treatment for the patient can be delayed by several days while awaiting fixation
of tissue, performance of IHC studies, and evaluation by a pathologist for a final pathological
diagnosis. Definitive treatment in this situation can vary from a return to the operating room
for surgical resection of the lesion in the case of glioma, versus chemoradiation therapy in the
case of lymphoma.
IHC was developed during the 1940s by Albert Coons [4]. This histopathological technique
generates contrast in cells and tissue by specifically targeting proteins with antibodies. IHC un-
doubtedly revolutionized the study of tissues in laboratory and clinical settings. With a series of
tissue preparation and staining procedures, IHC can provide specific tissue information within
24–48 hours [5, 6]. However, with the advent of new imaging technologies and fluorescent mo-
lecular probes, it may be possible to develop protocols for generating IHC-like information in a
fraction of the time required by antibodies [7]. If these diagnoses could be made within intrao-
perative timeframes, they could offer immediate information to the surgeon, who can then
make surgical decisions intraoperatively. We sought to design a probe with sufficient speed
and accuracy to provide IHC-quality diagnoses in a surgically relevant time frame and to test
that probe in brain tumor model systems.
Aptamers are a newer class of target-recognizing molecular probes. They are deoxyribonu-
cleic acid (DNA), ribonucleic acid (RNA), or peptide strands with unique secondary or tertiary
structures that can bind to target molecules with high affinity and specificity [8–10]. Aptamers
can be generated from a synthetic DNA or RNA pool through an in vitro selection method
known as systemic evolution of ligands by exponential enrichment [9, 10]. The selected apta-
mer probes can bind molecular targets with IHC-like specificity in a fraction of the time re-
quired by antibodies. Reports have been published which describe aptamers used as
recognition molecules for tumor cell identification with various molecular targets [11–13]. In
this study, we build from these initial findings to investigate the utility of aptamers for intrao-
perative histopathological assessments.
Histopathological applications, whether antibody- or aptamer-based, require optimized
staining protocols to minimize nonspecific staining. Molecules such as blocking serum, bovine
serum albumin, and/or transfer RNA (tRNA) are routinely added during the staining process
to reduce nonspecific interactions [14, 15]. Then repetitive washing steps are used to minimize
nonspecific staining with aptamers and antibodies. To circumvent this, we developed fluores-
cently coupled aptamers that are activated upon specific binding-induced conformational
change and visualized through the principle of Förster Resonance Energy Transfer (FRET),
which has been previously described [16–18]. This can effectively produce an agent that is op-
tically silent until bound and “switches on” after binding to a specific target [16]. This decreases
the noise due to nonspecific binding and eliminates the need for multiple time-consuming tis-
sue preparation, staining, and rinsing procedures.
To test whether aptamers specifically label neoplastic brain tissue in a manner that would be
practical and timely for clinical intraoperative neuropathological use, we constructed a
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switchable aptamer complex against a human central nervous system (CNS) lymphoma cell
line. We extended a previously reported aptamer [14, 19] to include a fluorophore and a fluo-
rescence quencher to minimize signal in its unbound confirmation. Tested on human tumor
cells and fresh tissue from animal models of CNS lymphoma and glioma, we determined
whether this probe could rapidly distinguish human lymphoma cells similar to the clinical
standard of CD20 immunohistochemistry.
Materials and Methods
Preparation of Q-TD05
All DNA oligonucleotides were purchased from Integrated DNA Technologies, CA with high
performance liquid chromatography (HPLC) purification. A truncated version of TD05 apta-
mer, TD05 [17, 19] was used in our study.
The name and sequence of fluorophore-labeled aptamers are as follows:
TD05: 5’ /5Alex488N/AGG AGG ATA GTT AGG TGG CTG TTG AGG GTC TCC TCC
TA 3’
Q-TD05: 5’ /5Alex488N/AGG AGG AGA TTT TTT TTT TAG GAG GAT AGT TAG GTG
GCT GTT GAG GGT CTC CTC CTA /3BHQ_1/ 3’
Random aptamer (LD20t): 5' FITC-TAG CCA AGG TAA CCA GTA CAA GGT GCT AAA
CGT AAT GGC TTC GGC TTA C 3'
Cell culture
Human glioma cells (U251) and human CNS lymphoma (Ramos) cell lines were acquired
from American Type Culture Collection. U251 cells were cultured with Dulbecco’s Modified
Eagle Medium media supplemented with 10% fetal bovine serum (FBS), and Ramos cells were
cultured in Roswell Park Memorial Institute Medium (RPMI) 1640 supplemented with 10%
FBS and 50μM 2-mercaptoethanol (all from Invitrogen, Grand Island, NY). Cells were grown
at 37°C in a humidified incubator under 5% CO2. In some experiments, tumor cells were in-
fected with a lentivirus to introduce expression of red fluorescent protein (RFP) following the
manufacturers’ protocol.
In vitro labeling
The aptamer probes were diluted to 1μM in aptamer binding buffer (6.05 mMMg2+, 1.2 mM
Ca 2+, 4.5g/L glucose and 0.2% NaN3 in PBS buffer) and heated to 94°C for 5 minutes, followed
by immediate chilling on ice for 10 minutes. The annealed aptamers were mixed with yeast
tRNA (0.1 mg/mL) to block nonspecific binding and the prepared acute tissue slices were
soaked in the above aptamer solution and incubated on ice for 1 hour before confocal imaging.
Flow cytometry
Cultured U251 cells and Ramos cells were collected and washed twice by the aptamer binding
buffer. The annealed aptamers were diluted to 200nM in the binding buffer and added to 5 x
105 cells. The aptamer-cell mixture was incubated on ice for 15 minutes, and analyzed by
FACSCalibur from BD Biosciences with or without washing.
Animals
Crl:NIH-Foxn1rnu rats (5 weeks age) were obtained from The Charles River Laboratories Inter-
national, Inc. (Wilmington, MA). All experiments were performed in accordance with the
guidelines and regulations set forth by the National Institutes of Health Guide for the Care and
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Use of Laboratory Animals. Experiments were approved by the Institutional Animal Care and
Use Committee of the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Cen-
ter, Phoenix, Arizona.
Intracranial implantation
Rats were anesthetized by intramuscular injection of 10 mg/kg xylazine and 80 mg/kg ketamine
and placed in a small animal stereotactic headframe (Model 900, David Kopf Instruments,
Tujunga, CA). A 7-mm incision was made starting between the animal’s eyes to expose breg-
ma. A bur hole was made 3.5 mm lateral to bregma. U251 or Ramos cells were infused at a
depth of 4.5 mm below the surface of the brain after the syringe (Hamilton) was advanced 5.0
mm to create a 0.5-mm pocket. The cell suspension was infused using a UMP3-1 UltraMicro-
Pump microinjector (WPI, Sarasota, FL) set to a volume of 10 μL with an infusion rate of
3.00 μL/minute. The needle was withdrawn 2 minutes after the injection to minimize backflow
of the cell suspension. The bur hole was covered with bone wax, the skin incision was sutured,
and the rats were allowed to recover.
Acute slices
Twenty-eight days after implantation, rats were deeply anesthetized using the xylazine/keta-
mine mixture described previously. They were immediately decapitated, and their brains were
removed. Coronal slices (350 μm thick) were immediately cut from the cerebral cortex on a
Leica VT1200 vibratome in artificial cerebrospinal fluid containing the following (in mM): 126
NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 MgSO4, 2 CaCl2 and 10 glucose, pH 7.4. Acute
slices were incubated in aptamer solution for 60 minutes.
Aptamer and CD20 antibody colabeling
Fixed xenograft slices (3 slices from 2 animals) were washed and incubated in anti-CD20 pri-
mary antibody (Millipore; 1:250). Sections were then rinsed, incubated with AlexaFluor594
secondary antibody (Invitrogen), rinsed again, and counterstained with Q-TD05 aptamer. La-
beled sections were mounted on slides with vectashield (Vector labs) and No 1.5 coverslips
(VWR). Total antibody staining time was 24 hours and aptamer staining time was 1 hour.
Imaging
Aptamer labeled samples were placed in uncoated No.1.5 glass-bottom dishes and positioned on
the stage of a Zeiss 710 laser scanning confocal microscope equipped with a 40x/1.2NA water
emersion objective. We imaged Q-TD05 by exciting the fluorophore with a 489-nm diode laser
and collecting 505nm-535nm emission. We imaged red fluorescent protein by exciting with a
561nm laser and collecting 595nm-625nm emission. Spectral imaging was performed utilizing a
34 channel spectral detector, and separating emission every 10nm between 405nm-745nm. The
confocal aperture was set to one Airy unit for imaging. The laser and gain values were set to fill
the dynamic range of the photomultiplier tube, and the frame size was set to sample at Nyquist.
All post-image processing was conducted with NIH imageJ utilizing linear functions.
Results
Development of a FRET-based aptamer for detecting CD20 positive B
cells
Aptamer TD05, which binds to the heavy mu chain of membrane bound immunoglobulin in
CD20-positive Burkitt’s lymphoma cells, has been reported previously [14, 19]. In this study, a
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single stranded DNA linker is added to the existing TD05 aptamer sequence to create the
switchable probe “Q-TD05.” The fluorophore, AlexaFluor488, is chemically modified at the 5’
end of this probe, while a Black Hole Quencher (Integrated DNA Technology. Coralville,
Iowa) is modified at the 3’ end during chemical synthesis. Conceptually, the aptamer would be
minimally fluorescent in its unbound confirmation (designated as “resting” status) and in-
crease in fluorescence after binding to its target (designated as “bound” status; Fig 1A). Under
macrofluorescence, we observed the quenched and unquenched aptamer exhibited markedly
altered fluorescence (Fig 1B).
The constructed probe was first analyzed by fluorometry to confirm the quenching of the
fluorophore (Fig 1C). Here, we included a positive control where the fluorophore was directly
labeled at the 5’ end of TD05 aptamer (designated as the “on” TD05 probe). As shown in Fig
1C, the switchable probe in the absence of its target molecule shows a nearly 8 fold decrease in
Fig 1. Aptamer fluorescence unquenching. (A, B). A) Illustration of aptamer fluorescence unquenching with binding to molecular target. B)
Macrofluorescence change in fluorescence emission between quenched and unquenched aptamers. Target-binding induced change in fluorescence (C, D).
C) Fluorescence emission intensity of the unquenched probe versus the quenched. Note a near 8-fold change in fluorescence intensity. D) Fluorescence
intensity of the quenchable aptamer tested on negative control T cells and positive control B cells. Note increased fluorescence and number of labeled B cells
versus T cells.
doi:10.1371/journal.pone.0123607.g001
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fluorescence intensity compared to the “on” probe in the unquenched confirmation. This indi-
cated the switchable probe is truly in resting status, and is expected to exhibit very low back-
ground signal when is used for cell or tissue staining.
To confirm this expectation, we then incubated the aptamer probes on cultured human lym-
phoma cell lines for 15 minutes and analyzed by flow cytometry (S1 Table). Fluorescence signal
caused by nonspecific binding is commonly seen in regular aptamer staining without a washing
step. This results in artificial positive cell labeling, especially when applied to tissues. Here, the
background staining is compared in the cell lines without washing. The percentage of cells that
were artificially labeled in the negative control cell line was used as a parameter to compare the
background level (also known as noise) between the “on” probe and the switchable probe. In
the group stained with the switchable aptamer probe, the background nonspecific labeling of
negative control cells was reduced to about 1/7 (11.77% vs. 81.90% in (Fig 1D) of that in the
group stained with the “on” aptamer probe. As an additional control, we incubated B cells with
a random fluorescent aptamer and found their fluorescence signal to resemble baseline noise
(Fig 1D). This demonstrates that the switchable aptamer could reduce the background staining
of non-target cells and could potentially provide specific contrast during tissue staining.
Quenched TD05 specifically differentiates B cell lymphoma from
astrocytoma cells
To test whether our aptamer could differentiate clinically meaningful tumor cell types, we test-
ed Q-TD05 on human B cell lymphoma and human astrocytoma cells. Human lymphoma and
astrocytoma were first virally transduced with lentivirus to constitutively express red fluores-
cent protein for specific visualization of tumor cells (Fig 2B and 2E). Fluorescence imaging of
lymphoma cells incubated with Q-TD05 revealed a ring-like staining pattern that is typically
seen when using CD20 antibody, a common lymphoma marker on lymphoma cells (Fig 2A)
[20]. Fluorescence imaging of astrocytoma cells revealed no cell-specific staining (Fig 2D). We
noted that Q-TD05 produced some fluorescent artifacts in lymphoma and astrocytoma tissues
which differed in morphology from the positive ring-like staining characteristic of CD20
immunostaining (Fig 2 arrowheads). This shows Q-TD05 can differentiate human B cell lym-
phoma and astrocytoma in cell culture based on fluorescence and staining pattern.
Comparison of Q-TD05 staining in xenograft acute slices and fixed slices
(Quenched TD05 differentiates human B cell lymphoma from
astrocytoma in xenograft acute slices)
In order to test Q-TD05 on tissues that more resemble a clinical biopsy, we generated brain
slices from rodents intracranially implanted with human B cell lymphoma and astrocytoma
cells (n = 12 lymphoma slices from 5 animals and n = 5 astrocytoma slices from 3 animals),
and compared the staining patterns. Fresh acute tissue slices containing tumor were incubated
with Q-TD05 for one hour and imaged on a confocal microscope. In acute slices containing B
cell lymphoma, we found cells with a fluorescent ring-like staining pattern that resembled clas-
sic CD20 antibody staining (Fig 3A). On fresh tissue containing human astrocytoma cells we
found minimal nonspecific fluorescence and an absence of a ring-like staining pattern (Fig 3B).
Much like astrocytoma samples, fresh tissue from normal rodent brain incubated with
Q-TD05 only produced weak fluorescence and fluorescence hypointensity of cell bodies (Fig
3C). Next, we examined if active processes were important to the aptamer signaling by examin-
ing for similar staining in fixed tissue. We tested Q-TD05 on fixed xenograft brain slices from
animals implanted separately with either a B cell lymphoma or astrocytoma. We found a strong
fluorescence ring-like staining pattern of cells within lymphoma tumor regions. This was
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contrasted to weak fluorescence of tissue outside the lymphoma tumor margin (Fig 3D). Fixed
astrocytoma slices incubated with Q-TD05 produced only weak fluorescence and were absent
of the observed CD20-like staining pattern from fixed lymphoma tissue (Fig 3E). Spectral im-
aging verified fluorescence signals we detected were fluorophore-specific (S1 Fig). Unique to
fixed tissue, we found increased fluorescent artifacts compared to fresh tissue. However, these
artifacts did not recapitulate a CD20 circumferential staining pattern (Fig 3F). These results in-
dicate that specific tissue preparation such as fixation is not needed, and may actually reduce
the quality, for Q-TD05 staining. Removing time-consuming washing or fixation procedures
significantly reduces the complexity of staining and highlights the benefit of the Q-TD05
staining method.
Quenched TD05 localizes to fluorescent B cell lymphoma cells in
xenograft slices
To visualize the localization of Q-TD05 and examine the labeling accuracy, we produced ro-
dent xenografts with human B cell lymphoma and astrocytoma cells expressing red fluorescent
protein (RFP) (n = 4 lymphoma and 3 astrocytoma slices). Fresh acute slices generated from
these animals were incubated with Q-TD05 for one hour and imaged without rinsing. We
found strong circumferential staining of RFP-labeled lymphoma cells with Q-TD05 (Fig 4A–
4C). Acute slices from astrocytoma xenografts showed strong RFP expression but lacked cir-
cumferential staining (Fig 4D–4F). As an additional negative control, we did not find fluores-
cently labeled cells in acute slice normal brain regions (Fig 4G–4I). We quantified labeling of
Fig 2. Quenchable aptamer staining of cultured human fluorescent lymphoma and astrocytoma cells. (A-C) Lymphoma. A) B cell lymphoma cells
incubated with the quenchable aptamer; note ring-like staining pattern (arrows) and fluorescent artifacts (arrowheads). B) Lymphoma cells expressing RFP.
C) Merged image of RFP-lymphoma cells and aptamer staining. (D-F) Astrocytoma. D) Astrocytoma cells incubated with the quenchable aptamer; note
fluorescent artifacts (arrowheads) and lack of ring-like staining. E) Astrocytoma cells expressing RFP. F) Merged image of RFP-astrocytoma cells and
aptamer staining. Scale bars equal 20um. © 2015, Barrow Neurological Institute, provided under CC BY 4.0.
doi:10.1371/journal.pone.0123607.g002
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Q-TD05 to RFP-labeled lymphoma cells (n = 13 fields of view from 3 acute slices). We found
Q-TD05 labeled a significantly greater percentage of RFP-labeled lymphoma cells than non-
RFP labeled cells (80.75 ± 2.52% vs. 8.25 ± 1.51%, p<0.001), and a strong correlation between
aptamer staining and RFP-expressing lymphoma cells (R2 = 0.92, p<0.001) (Fig 4J and 4K).
Discussion
We have demonstrated the potential of a FRET-based aptamer for providing antibody-specific
diagnostic information in a small fraction of the time required for traditional IHC in cell cul-
ture and in an animal model. Specifically, we tested the specificity of Q-TD05 in human cell
culture and tissues from orthotopic rodent xenografts. Compared with the current standard of
CD20 IHC, Q-TD05 provided significantly faster identification of lymphoma cells with a less
complex staining procedure (Supplemental Fig 1). Coupled with fluorescence imaging,
Q-TD05 allowed rapid differentiation of human lymphoma cells from a clinically meaningful
negative control of human astrocytoma based on staining intensity and morphology.
Antibody staining can be a rate-limiting step for definitive surgical treatment of cancers.
When intraoperative histopathological diagnostics cannot differentiate cancers with opposing
treatment paradigms such as CNS lymphoma versus astrocytoma, antibody staining is utilized
Fig 3. Xenograft acute slices. (A-C) Fresh tissue. A) Tumor region of B cell lymphoma acute slice incubated with the quenchable aptamer. Note the ring-like
staining pattern. B) Tumor region of astrocytoma acute slice; note lack of ring-like staining pattern. C) Contralateral normal brain from lymphoma acute slice.
Note hypo-fluorescent regions indicating location of cell-bodies. (D-F) Fixed tissue. D) Fixed acute slice containing B cell lymphoma; note positive cells in
hypercellular tumor region (arrows). E) Fixed astrocytoma tissue lacking positive staining; note absence of positive cells within hypercellular tumor (arrows).
F) Contralateral normal brain from lymphoma fixed slice; note additional fluorescent artifacts (arrowheads). Scale bars equal 20um. © 2015, Barrow
Neurological Institute, provided under CC BY 4.0.
doi:10.1371/journal.pone.0123607.g003
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Fig 4. Fluorescent xenograft acute slices. (A-C) Lymphoma. A) Aptamer staining of lymphoma acute slice
with positive staining regions (arrowheads). B) RFP-expressing lymphoma cells within tissue slice. C) Merge
(D-F) Astrocytoma. D) Aptamer staining of astrocytoma acute slice; note lack of positively stained cells. E)
RFP-expressing astrocytoma cells within tissue slice. F) Merge. (G-I) Normal brain. G) Aptamer staining of
normal brain lacking aptamer-positive cells. H) Absence of ring-like staining and RFP-expressing cells in
normal brain. I) Merge. J) Q-TD05 labels 80.75 ± 2.52% of RFP-expressing lymphoma cells and 8.25 ± 1.51%
of non-RFP cells, p<0.001. K) Coefficient of correlation between RFP-lymphoma cells and aptamer staining
(R2) = 0.92 with 95% confidence intervals (dotted lines) of 0.87–0.99, p<0.001. Scale bars equal 20um. ©
2015, Barrow Neurological Institute, provided under CC BY 4.0.
doi:10.1371/journal.pone.0123607.g004
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to differentiate tissue based on tumor-specific protein expression [3]. This method requires nu-
merous steps for tissue preparation and staining, and therefore typically requires at least 24–48
hours for processing [2, 6]. In contrast, our Q-TD05 aptamer identified CD20-positive tumor
cells in fresh and fixed tissue with a one-step staining protocol with no special tissue prepara-
tion. This was evident in tumor core regions and tumor margins which contain more heteroge-
nous cell populations (S1 Fig) [21]. Q-TD05 allowed antibody-like specific detection of CNS
lymphoma cells within 15–60 minutes. Though labeling with this proof-of-concept quenchable
aptamer exceeds the frozen section time range, it specifically labels lymphoma cells nearly two
orders of magnitude faster than IHC. Additionally, development of aptamers with enhanced
binding affinities is currently underway and could further decrease this staining time.
Advancements in optical imaging and development of fluorescent probes have provided re-
searchers powerful tools for characterizing tissue, and we believe great advances will be made by
applying these tools to intraoperative tissue diagnostics. The ability to make rapid and specific
intraoperative diagnoses could decrease surgical times, provide additional guidance to surgeons
in the operating suite, decrease the time patients are required to wait for a definitive diagnosis,
and potentially decrease healthcare costs by facilitating and expediting diagnosis-based treat-
ment decisions. Though the initial cost of fluorescence imaging equipment may be an obstacle
to widespread use of switchable-aptamers, the one-step staining protocol and rapid diagnostic
output could justify the expense, making them cost-effective with even moderate use. The attrac-
tiveness of much more rapid definitive pathological results will likely drive adoption. In addition,
current efforts to miniaturize and economize fluorescence imaging instruments will soon make
this imaging modality a realistic option for many pathology departments [22, 23].
Conclusion
We have demonstrated that a conformational FRET-based switchable aptamer targeting
human B cell lymphoma can rapidly and specifically identify tumor cells in biopsies from ro-
dent xenograft models of human brain tumors. Translated into clinical pathology, quenchable
aptamers have potential for providing intraoperative diagnoses not currently possible with fro-
zen sections. Development of these aptamers against additional clinical targets could provide
specific diagnoses in timeframes that support intraoperative decision-making and facilitate
clinical management of patients whose treatment depends on their pathological diagnosis.
Supporting Information
S1 Fig. Colabeling: TD05 and CD20 antibody. (A and D) Aptamer. B cell lymphoma xeno-
graft slices incubated with the quenchable aptamer; 1 hour staining. (B and E) CD20 antibody.
B cell lymphoma slices incubated with CD20 antibody; 24 hour staining time. (C and F) Merge.
Merged image of aptamer and CD20 antibody staining. (G) Spectral analysis. Ring-like staining
patterns contain strong 488nm and 594nm fluorescence emissions; wavelengths unique to
Q-TD05 and CD20 antibody. Scale bars equal 20μm. © 2015, Barrow Neurological Institute,
provided under CC BY 4.0.
(TIF)
S1 Table. Quantification of probe staining profile in cultured human B lymphoma cells
(Ramos, the CD20 positive cell line) and T lymphoma cells (Jurkat, the CD20 negative con-
trol cell line). The percentage of the positively stained population in each cell line is listed in
the table, and the signal/noise ratios are shown as the ratio between the percentage of positively
stained population in Ramos and Jurkat cells.
(DOCX)
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